کارگاه‌های آموزشی مرکز اطلاعات علمی

مقاله نویسی علوم انسانی

اصول تنظیم قراردادها

آموزش مهارت های کاربردی

در تدوین و چاپ مقاله
FISH Analysis for del6q21 and del17p13 in B-cell Chronic Lymphocytic Leukemia in Iranians

Hossein Teimori1*, Saeede Ashoori1, Mohamad Taghi Akbari2, Marjan Mojtabavi Naeini1, Morteza Hashemzade Chaleshtori1

1 Cellular and Molecular Research Center, School of Medicine, Shahrekord University of Medical Sciences, Shahrekord, IR Iran
2 Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, IR Iran

* Corresponding author: Hossein Teimori, Cellular and Molecular Research Center, School of Medicine, Shahrekord University of Medical Sciences, Shahrekord, IR Iran. Tel: +98-3813346692, Fax: +98-3813330709, E-mail: hosseintimm@yahoo.com.

ABSTRACT

Background: B-cell chronic lymphocytic leukemia (B-CLL) is the most common leukemia in the Western world. Major progress has been made in assessing typical chromosomal abnormalities and recognition of the correlation of these chromosomal abnormalities with laboratory features and clinical course of the disease. The most frequent genomic changes are deletions at 13q14, 11q22-23 and 17p13 and trisomy of chromosome 12.

Objectives: The aim of this study was to investigate the frequency of chromosomal aberrations in B-CLL patients’ peripheral blood and/or bone marrow using a molecular cytogenetic method, interphase fluorescence in situ hybridization (FISH) and to evaluate the correlation between these genomic changes and clinical findings.

Patients and Methods: FISH analyses were performed on bone marrow and blood samples of 66 B-CLL patients.

Results: Deletion of 17p13 was found in 11 (16.6%) and deletion 6q21 was present in 5 (7.5%). Statistical analyses were performed to investigate the correlation of these molecular-cytogenetic findings with family history, Rai staging and CD38 marker. No clear differences in distribution was noted for del17p13 and del6q21 among patients with and without family history, and no direct correlation was noted between these genomic changes and CD38 marker, but the correlation of del17p13 and Rai stage was significant. There was a high frequency of Rai stage II within del17p13 patients.

Conclusions: It was demonstrated that the presence of del6q21 in B-CLL patients indicates poor prognosis and on the contrary, presence of del17p13 points at the good prognostic value of the disease.

Keywords: Leukemia, Lymphocytic, Chronic, B-Cell; Cytogenetic Aberrations; Biological Markers

1. Background

B-cell chronic lymphocytic leukemia (B-CLL) is usually described as the most common leukemia in the United States, Canada, and Western Europe, whereas it is rare in Japan and infrequent in other Asian societies (1). CLL is with an incidence of 30% among the entire leukemia’s (2) as the matter of fact it is 20 new cases per 100,000 inhabitants above the age of 60 years. The reported male-to-female sex ratio is about 1.5–2:1, which means B-CLL is more common in men than women (3). It is a common cancer not even in the Western countries, but also in Iran (4). B-CLL results from the expansion of mature-appearing monoclonal B cells with a characteristic immu-
nophenotype (CD5, CD19, CD20, and CD23 positive) (5–7). Clinical course of the disease is highly variable. Some patients show symptoms at diagnosis or early thereafter and need early therapy, but others have no or minimal symptoms for many years (8). Infrequently, there are constitutional symptoms; on the contrary, the most frequent physical finding is lymphadenopathy, which is followed by splenomegaly. Other symptoms are fatigue, infection and autoimmune hemolytic anemia. There are several treatments for B-CLL patients such as using monoclonal antibodies, new experimental drugs and stem cell transplantation (autologous or allogeneic) (9). Variable prognosis is carried by B-CLL, which is associated with distinct parameters such as genetic aberrations that are helpful to predict the clinical outcome of the disease (10, 11). Age, sex, and clinical staging (Rai or Binet staging), peripheral blood lymphocyte count, lymphocyte-doubling time, bone marrow (BM) histology, serum thymidine kinase, and serum β2-microglobulin levels have all been identified as important independent prognostic factors (12–15). Chromosomal aberrations in B-CLL rose to more than 80% (16–18), which means that genetic markers could have a critical role in prediction and diagnosis of B-CLL. The most frequent aberrations are: 1) Deletion on the long arm of chromosome 13 (13q14) in > 50% of the cases (19); 2) Trisomy of chromosome 12 in 10–20% of the cases; 3) Deletions in bands 11q22–q23 in 10–20% of the cases, where the ATM gene is located (20–22); 4) Deletion on the short arm of the chromosome 17 (17p13). Association of Deletion 11q22 and 17p13 with poor prognosis and deletion 13q14 with good prognosis has been demonstrated (23). Trisomy 12 is correlated with atypical morphology and shortened survival (worse prognosis) (24, 25). Conventional cytogenetic methods can detect 40–50% abnormalities in B-CLL patients (26, 27), while using fluorescent in situ hybridization (FISH) has brought the sensitivity of cytogenetic analysis to a higher level, by which, 80% of abnormalities can be detected (28). In the previous study, we analyzed the correlation of del (13q), del (11q) and trisomy 12 with features of B-CLL in Iranian cases (29).

2. Objectives

The aims of this study were first to verify the frequency of del (6q21) and del (17p13) in B-CLL patients by conventional cytogenetic methods and FISH technique, and second to determine the correlation between these two abnormalities and prognostic factors, including Rai staging, CD38 marker and family history.

3. Patients and Methods

Patients were recruited for 20 months between 2008 and 2010 from four major hematology/oncology hospitals in Tehran, Iran. The patients were new cases or already identified as B-CLL cases and not taking any therapeutic treatment for six months before sampling. The diagnostic inclusion criteria were based on the National Cancer Institute Working Group (NCI-WG) guidelines for diagnosis of B-CLL (30). Seventy patients’ peripheral blood samples or bone marrow aspirations were analyzed. Immunophenotypic data and blood parameters were collected from patients’ hospital files. The questions about age, family history, the onset of disease and treatment measures were organized. The patients with one first or two second degree relatives affected by any type of cancer in their families were considered as positive family history. Blood samples and/or bone marrow aspirations were collected in heparinized collection tubes. The study was approved in Shahrekord Medical University and Ethical Committee of the School of Medical Sciences of Tarbiat Modares University. Each patient signed the written consent. Peripheral blood and bone marrow samples were pretreated by different protocols for culturing. 27 bone marrows, 36 blood samples and 7 of both specimens were provided. Peripheral blood was washed three times with minimal culture medium (RPMI-1960 with no further supplementation) and then the white blood cells (WBC) were counted by Neubauerhemocytometer. Bone marrow specimens only were counted by Neubauerhemocytometer. 106 cells/ml was cultured in 5 ml completed culture medium [RPMI-1960 medium (Gibco, USA), 10% fetal bovine serum (Gibco, USA), 1% antibiotics and 1% L-glutamine (Gibco, USA)]. Five cultures were set up for each patient whose conditions were as follows: overnight (ONC), 24 hours and 72 hours without mitogen stimulation and 24 hours and 72 hours with phorbolmyristate acetate (50 ng/mL) (Biomol, Germany). Harvesting and slide preparations were completed according to the standard cytogenetic methods (Hypotonic treatment, and methanol-acetic acid, Merk, Germany; 3:1 ratio of fixation). G-banding technique was used and up to 20 metaphases were analyzed for each patient utilizing Applied Imaging Powergene Intelligent Karyotyping software (Applied Imaging, USA) according to the International system for Human Cytogenetic Nomenclature (31). The FISH analysis was performed on slides taken from the 24-hour culture without stimulation. To evaluate del (6q21) and del (17p13), Dual-color probes were purchased from Kreatech Company and utilized according to the manufacturer’s instructions. For each probe per patient, two hundred nuclei were analyzed by Olympus BX51 fluorescence microscope (Japan). To capture images, Cytovision software, version 3.6, was used. SPSS software program (SPSS for Windows, version 15, Chicago, IL, USA) was used for statistical analysis. Correlations between family history and these two deletions were analyzed by Chi-Square test. The Mann-Whitney test was considered for analyzing the correlation between the Rai staging and chromosomal abnormalities. The Mann-Whitney test was used to evaluate the correlation between these chromosomal abnormalities and CD38. A p value less than 0.05 were considered significant.
4. Results

The culture of four cases failed, and 66 specimens were successfully analyzed. In Table 1, patients’ clinical characteristics are summarized. The gender ratio was 2.9 with 49 male and 17 female patients. Patients were 40 to 81 years old with the mean age of 61.73 years old. They could be classified into two subgroups. Twenty three cases have been recently diagnosed (new cases), and they were following their clinical diagnosis. Forty three cases suffered from the disease from 8 to 236 months. The number of bone marrow specimens in Table 1 is actually the sum of cases with bone marrow and cases with both bone marrow and peripheral blood samples. The information of Rai staging and family history is also available in Table 1.

| Patients | Genomic Changes | Total (n = 66) |
|----------|-----------------|---------------|
|          | Del 6q21 (n = 4) | Del 17p13 (n = 11) |     |
| Gender, No. |                  |                |     |
| Male     | 1                | 10             | 49  |
| Female   | 3                | 1              | 17  |
| Age, y, No. |                |                |     |
| < 50     | 0                | 1              | 8   |
| 50-60    | 0                | 4              | 17  |
| 60-70    | 2                | 4              | 25  |
| > 70     | 2                | 2              | 16  |
| Tissue   |                  |                |     |
| BMa      | 2                | 6              | 27  |
| PBa      | 3                | 6              | 32  |
| Rai stage|                  |                |     |
| O        | 0                | 0              | 6   |
| I        | 0                | 1              | 9   |
| II       | 3                | 3              | 31  |
| III      | 1                | 6              | 15  |
| IV       | 0                | 1              | 5   |
| Family history |            |                |     |
| Positive | 1                | 9              | 15  |
| Negative | 3                | 2              | 47  |

*a Abbreviation: BM, bone marrow; PB, peripheral blood*

Interphase FISH for del (6q21) and del (17p13) was performed on 66 patients; out of which 5 cases demonstrated the micro deletion in 6q21 (5/66 or 7.5%); and 11 cases turned out to have the micro deletion in 17p13 (11/66 or 16.6%); among these 16 patients with these chromosomal abnormalities, one patient had both del (6q21) and del (17p13). The range of abnormalities was different in patient’s specimens. Compared to cut off points for positive values, this range verified the abnormalities in patients properly. Correlation of family history and del (17p13) were analyzed by Chi square (P = 0.48 for Fisher’s exact test) and did not show any significance. This test also was performed between family history and del (6q21) (P = 0.048 for Fisher’s exact test) but the correlation was not significant. The Mann-Whitney test was considered for analyzing the correlation between Rai staging and del (6q21). The result was P = 0.7, which means there is no significance. This test was repeated for the correlation of chromosomal abnormalities and CD38. The result for del (6q21) and del (17p13) was P = 0.368 and P = 0.13 respectively, which means CD38 did not have significance in any of these two abnormalities. FISH analysis revealed 22.7% chromosomal abnormalities in total comprising 7.5% for del (6q21) and 16.6% for del (17p13). The results of other published studies and the current study are summarized in Table 2.

5. Discussion

CLL is the most prevalent type of leukemia, but its annual incidence of new cases is low and consequently; the number of new cases is generally low (4). So in the present study the number of new cases hardly comprises one-third of all cases. The gender ratio shifted towards more
males because, some female patients avoided to take part in the study. There were two reasons why bone marrow specimens were less than peripheral blood samples. First, the greater numbers of cases were those who had already been diagnosed as B-CLL and the physicians did not feel necessary to perform another bone marrow aspiration; second, an analysis of both bone marrow and blood samples demonstrated that there are no differences between these two tissues in FISH results and patients prefer to give blood samples instead of bone marrow aspiration. So the number of peripheral blood specimens increased in this study. The weak mitogen stimulation of malignant cells in B-CLL and the fact that in B-CLL unlike other forms of leukemia, the cells are in G0 phase of the cell cycle, we had a decrease of metaphases in the cytogenetic analysis. Moreover, many of the chromosomes were small and short and less liable to good banding. So it was so difficult to identify chromosomal abnormalities such as translocations, inversions and micro deletions. Because of these reasons, we could just identify 27.7% chromosomal abnormalities using conventional cytogenetic methods.

As mentioned before, up to 80% of chromosomal abnormalities in B-CLL patients could be detected using I-FISH (43). Oscier et al. (44), using FISH; found chromosomal aberrations in 69% of patients, Dewald et al. (41), found 77%; Chena et al. (2), 80.7%; Gunn et al. (32), 89%; and Dohner et al. (17), 82%. In some of these studies (17, 41), B-CLL patients were examined for deletion of 8q, 11q, and 17p; also for 6q, 14q chromosomal abnormalities and for 8q24 and 3q trisomy (17). So the rate of chromosomal aberrations detected by FISH is high. The greater detection of chromosomal abnormalities by FISH method in comparison to conventional cytogenetic methods reveals the higher sensitivity of this method. Therefore, FISH testing helps outstandingly in establishing a diagnosis for these patients. In our study where I-FISH was only used for two genomic changes and patients were examined with two DNA probes (for detection of deletion 6q21 and deletion 17p), we could detect these abnormalities in just 22.7% of patients, comprising 16.6% for del 17p13 and 7.5% for del 6q21. The results of this study and some similar studies are summarized in Table 2. We found deletion of TP53 gene on 17p13 in 11 (16.6%) of studied cases. In addition to deletion of 17p13 chromosomal band or occurring mutations in TP53 gene, inactivation of this gene could be because of other factors. For example Pettitt et al. (45) revealed that p53 inactivation occurred because of defects of ATM protein, which has a role in dephosphorylation of p53. Some other studies have shown that deletion of 17p13 band has a significant effect on clinical course of the disease. B-CLL patients with deletion of TP53 gene have an obvious shorter survival time and show failure to treatment with purine analogs (17, 34, 46, 47). Anomalies of short arm of chromosome 6 are reported from 0-10% (33, 36, 41). In this region most abnormalities are deletions and diverse regions have been identified at 6q5, 6q21, 6q23 and 6q25-27 (48, 49). Stilgenbauer et al. showed that 6q21 is the most commonly deleted region and 6q27 deletion occurs only in patients with del (6q21) (50). The genes in this region which are involved in the pathogenesis of the disease are not known yet but the TLX gene at 6q21 has been shown to be involved in non-Hodgkin’s lymphoma patients (51, 52). In analysis of clinical importance of 6q deletions in B-CLL patients contentious results were observed. While Juliusson et al. (37) didn’t observe any poor prognostic effect of del (6q), Oscier et al. (53) observed that those patients with del (6q) had shorter survival times without treatment. In our study, del (6q21) was detected in 5 (7.5%) of studied cases. One of the patients had both abnormalities, del (6q21) and del (17p13). As it is evident, the frequency of patients with del (17p13) and del (6q21) and so the type and the rate of these abnormalities in Iranian patients is similar to those in other populations. This sug-

Table 2. Detection Rate of Cytogenetic Aberrations by FISH Analysis in Different Populations

| No | Reference          | Country       | Del 17p13, % | Del 6q21, % | FISH Abnormality, No. (%) |
|----|--------------------|---------------|--------------|-------------|--------------------------|
| 1  | Gunn et al. (32)   | USA           | 4.6          | 7.5         | 174 (89)                 |
| 2  | Gaidano et al. (33)| USA           | 4            | 10          | 100 (14)                 |
| 3  | Dohner et al. (34) | Germany       | 12           | -           | 90 (12)                  |
| 4  | Dohner et al. (17) | Germany       | 7            | 6           | 325 (82)                 |
| 5  | Chevallier et al. (35)| France     | 7            | -           | 11 (75)                  |
| 6  | Haferlach et al. (36)| Germany    | 7            | 4.6         | 500 (78.4)               |
| 7  | Juliusson et al. (37)| Sweden    | 4            | 6           | 649 (48)                 |
| 8  | Turgut et al. (38) | Turkey        | 14           | -           | 36 (47)                  |
| 9  | Sindelarova et al. (39)| Czech republic | 16          | -           | 206 (16)                 |
| 10 | Durak et al. (40)  | Turkey        | 7.6          | -           | 79 (50.6)                |
| 11 | Dewald et al. (41) | USA           | 8            | 0           | 113 (77)                 |
| 12 | Dicker et al. (42) | USA           | 5.3          | 7           | 132 (79)                 |
| 13 | Present study      | Iran          | 16.6         | 7.5         | 66 (22.7)                |
gests that probable mechanisms involved in this disease are not different from patients from other countries.

As far as, correlation between clinical staging, family history and immunophenotyping with these two cytogenetic subgroups is concerned, after statistical analysis, significant correlation was only shown between Rai staging and del(17p13). This deletion has the most frequency in Rai stage II, so Rai stage II could be somehow a prognostic factor for this deletion. We can arrange Rai stages in descending sort (II, III, I, O, IV) for this correlation. Cases with familial B-CLL comprise about 5% of B-CLL patients. Cytogenetic and immunophenotypic results of familial and sporadic B-CLL patients were similar to each other. Some other studies analyzing familial B-CLL cases have also suggested similar findings (54, 55).

Acknowledgements
None declared.

Financial Disclosure
None declared.

Funding/Support
None declared.

References
1. Faguet GB. Chronic Lymphocytic Leukemia: Molecular Genetics, Biolo-
   gy, Diagnosis, and Management. New Jersey: Humana Press; 2004.
2. Chena Christian, Arrossagaray Guillermo, Scolnik Mariano, Pal-
   cios Maria F, Slavutsky Irma. Interphase cytogenetic analysis in Argen-
   tinean B-CLL chronic lymphocytic leukemia patients: associ-
   ation of trisomy 12 and del(16p). Cancer genetics and cytogenet-
   ics.2003;134(6):254-60.
3. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J
   Med.1995;333(16):1052-7.
4. Karimi M, Mehrabani D, Yarmohammadi H, Jahromi FS. The
   prevalence of signs and symptoms of childhood leukemia and
   lymphoma in Fars Province, Southern Iran. Cancer Detect
   Prev.2008;32(2):237-83.
5. Caligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leuke-
   mia: a bird of a different feather. Clin Oncol 1999;11(1):399-408.
6. Dierlamm J, Michaelsen L, Creda A, Wodarska I, Van den Berge H,
   Hossfeld DK. Genetic abnormalities in chronic lymphocytic leu-
   kemia and their clinical and prognostic implications. Cancer
   Genet Cytogenet.1997;94(2):27-35.
7. Hamblin TJ, Davis Z, Gardiner A, Osier DG, Stevenson FK. Unmu-
   tated IgVH genes are associated with a more aggressive form of
   chronic lymphocytic leukemia. Blood.1999;94(6):1848-54.
8. Zena T, Dohner H, Stilgenbauer S. Genetics and risk-stratified ap-
   proach to therapy in chronic lymphocytic leukemia. Best Pract
   Res Clin Haematol.2007;20(3):439-53.
9. Pangalis GA, Vassilakopoulos TP, Dimopoulou MN, Siakantaris
   MP, Kontopodis FN, Angelopoulos MK. B-chronic lymphocytic
   leukemia: practical aspects. Hematol Oncol.2002;20(3):203-46.
10. Amiel A, Leopold L, Gronich N, Yukla M, Feigin MD, Lishner M. The
    influence of different chromosomal aberrations on molecular
    cytogenetic parameters in chronic lymphocytic leukemia. Can-
    cer Genet Cytogenet.2006;167(2):145-9.
11. Osier D, Biology and prognostic factors in CLL. Hematolo-
    gy.2005;30 suppl 1:97-9.
12. Binet J, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen
   J, et al. A new prognostic classification of chronic lymphocytic
   leukemia derived from a multivariate survival analysis. Can-
   cer.1981;48(4):398-206.
13. Doneda Luisa, Montillo Marco, Intropido Liliana, Tedeschi Ales-
    sandra, Morra Enrica, Larizza Lidia. Interphase fluorescence in
    situ hybridization analysis of del(11)(q23) and del(17)(p13) in
    chronic lymphocytic leukemia: a study of 40 early-onset pa-
    tients. Cancer genetics and cytogenetics.2003;140(3):238-36.
14. Rai KR, Sawaiyki A, Cronkite EP, Chanaana AD, Levy RN, Pastern-
    ack BS. Clinical staging of chronic lymphocytic leukemia. Blood.
   1975;45(2):209-34.
15. Shahinlshf, Geyer SM, Kay NE. Prognosis at diagnosis: integrat-
    ing molecular biological insights into clinical practice for pa-
    tients with CLL. Blood.2004;103(4):1522-40.
16. Bentz M, Huck K, du Manoir S, Joos S, Werner CA, Fischer K, et
   al. Comparative genetic hybridization in chronic B-cell leuke-
   mia shows a high incidence of Chromosomal gains and losses.
   Blood.1995;85(12):3610-8.
17. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bull-
    inger I, et al. Genomic aberrations and survival in chronic lym-
    phocytic leukemia. N Engl J Med.2003;348(26):2490-6.
18. Odero MD, Soto H, Murayama M, Martin Baben I, Zudaire L, Rao PH, et
   al. Comparative genetic hybridization and amlysotyping by
    arbitrarily primed PCR in stage A B-CLL. Cancer Genet Cytogenet.
   2001;130(1):61-70.
19. Calin GA, Dumitru CD, Shumizzu M, Bichi R, Zupo S, Noch E, et al.
  Frequent deletions and down-regulation of micro RNA genes miR15
    and miR16 in B-CLL. Proc Natl Acad Sci U S A.2004;101(24):8592-9.
20. Bullrich F, Rasio D, Kitada S, Starostik P, Kipps T, Keating M, et
    al. ATM mutations in B-cell chronic lymphocytic leukemia. Can-
    cer Res.2009;69(24):9971-6.
21. Schaffner C, Stilgenbauer S, Rappold GA, Dohner H, Lichter P. So-
    matic ATM mutations indicate a pathogenic role of ATM in B-cell
    chronic lymphocytic leukemia. Blood.1999;94(2):748-53.
22. Stankovic T, Weber P, Steward G, Bedenham T, Murray J, Byrd PJ, et
   al. Inactivation of ataxia telangiectasia mutated gene in B-cell
    chronic lymphocytic leukemia. J Clin Oncol.1998;16(24):3705-8.
23. Sanchez J, Aventin A. Detection of chromosomal abnormalities
    in chronic lymphocytic leukemia increased by interphase
    fluorescence in situ hybridization in tetradecanoylphorbol
    acetate-stimulated peripheral blood cells. Cancer Genet Cytogenet.
   2007;175(5):275-57.
24. Criel A, Verhoed G, Vlieinck R, Mecucci C, Billet J, Michel X, et
   al. Further characterization of morphologically defined typical
   and atypical CLL: a clinical, immunophenotypic, cytogenetic and
   prognostic study on 390 cases. Br J Haematol.1999;107(3):383-91.
25. Hjalmar V, Kimby E, Matutes E, Lundstrom C, Jacobsson B, Arvidsson I, et al. Trisomy 12 and lymphoplasmacytoid lym-
    phocytes in chronic lymphocytic B-cell disorders. Haematologi-
    ca.1999;88(7):502-9.
26. Gahtoon G, Robert KH, Friberg K, Zech L, Bird AG. Nonran-
    dom chromosomal aberrations in chronic lymphocytic leu-
    kemia revealed by polyclonal B-cell-mitogen stimulation. Blood.
   2006;108(4):1540-7.
27. Hurley JN, Fu SM, Kunkel HG, Chaganti RS, German J. Chromo-
    some abnormalities of leukaemic B lymphocytes in chronic lym-
    phocytic leukaemia. Nature.1980;285(5742):76-8.
28. Montillo M, Hamblin T, Hallek M, Montserrat E, Morra E. Chronic
    lymphocytic leukaemia: novel prognostic factors and their rel-
    evance for risk-adapted therapeutic strategies. Haematologi-
    ca.2005;90(3):391-9.
29. Teimori H, Akbari M, Tooghe G, Khalighian M. Correlation of
    del(17p), del11q and Trisomy 12 with Laboratory and Clinical Fea-
    tures in 390 cases. Br J Haematol.1995;91(1):57-60.
30. Hessman BS. Clinical staging of chronic lymphocytic leukemia.
    Arch Intern Med.1975;46(3):249-51.
31. FISH Analysis in B-cell Chronic Lymphocytic Leukemia Teimori H et al.
    www.SID.ir
hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia. J Mol Diagn. 2008;10(5):442-51.

33. Gaidano G, Newcomb EW, Gong JZ, Tass V, Neri A, Corteleez-Zi A, et al. Analysis of alterations of oncogenes and tumor suppressor genes in chronic lymphocytic leukemia. Am J Pathol. 1999;144(6):1312-2.

34. Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood. 2002;100(4):3177-84.

35. Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, Stankovic T. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood. 2001;98(3):842-2.

36. Dohner H, Stilgenbauer S, Dohner K, Bentz M, Lichter P. Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis. J Mol Med (Berl). 1999;77(2):266-81.

37. Stilgenbauer S, Bullinger L, Lichter P, Dohner H. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia. 2002;16(6):993-1007.

38. Juliaussen G, Oscier DG, Fletcher M, Ross FM, Stockill D, Mackie MJ, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med. 1993;329(3):200-4.

39. Offit K, Louie DC, Parsa NZ, Filipia D, Gangi M, Siebert R, et al. Clinical and morphologic features of B-cell small lymphocytic lymphoma with del(6)(q22). Blood. 1999;94(9):2601-8.

40. Stilgenbauer S, Bullinger L, Bentz A, Wildenberger K, Bentz M, Dohner K, et al. Incidence and clinical significance of 6q deletions in B cell chronic lymphocytic leukemia. Leukemia. 1999;13(9):1338-4.

41. Jackson A, Panayiotidis P, Foroni L. The human homologue of the Drosophila tailless gene (TLX): characterization and mapping to a region of common deletion in human lymphoid leukemia on chromosome 6q21. Genomics. 1998;50(1):34-43.

42. Sherratt T, Morelli C, Boyle JM, Harrison CJ. Analysis of chromosome 6 deletions in lymphoid malignancies provides evidence for a region of minimal deletion within a 2-megabase segment of 6q21. Chromosome Res. 1997;5(2):238-4.

43. Oscier DG, Stevens J, Hamblin TJ, Pickering RM, Lambert F, Fletcher M. Correlation of chromosome abnormalities with laboratory features and clinical course in B-cell chronic lymphocytic leukemia. Br J Haematol. 1997;96(3):352-8.

44. Aoun P, Zhou G, Chan WC, Page C, Neth K, Pickering D, et al. Familial B-cell chronic lymphocytic leukemia: analysis of cytogenetic abnormalities, immunophenotypic profiles, and immunoglobulin heavy chain gene usage. Am J Clin Pathol. 2007;127(1):38-46.

45. Ng D, Toure O, Wei MH, Arthur DC, Abassi F, Fontaine L, et al. Identification of a novel chromosome region, 13q21.33-q22.2, for susceptibility genes in familial chronic lymphocytic leukemia. Blood. 2007;109(3):916-25.
کارگاه‌های آموزشی مرکز اطلاعات علمی

مقاله نویسی علوم انسانی

اصول تنظیم قراردادها

آموزش مهارت های کاربردی در تدوین و چاپ مقاله